Category: Cancer Research

Jazz Pharmaceuticals reports that Ziihera® (zanidatamab-hrii) has received FDA for the treatment of adults with HER2-positive (IHC 3+) biliary tract cancer (BTC) that has been previously treated and is either incurable or metastatic

The U.S. Food and Drug Administration (FDA) gave Ziihera® (zanidatamab-hrii) expedited approval on November 20, 2024, for the treatment of people with HER2-positive (IHC 3+) biliary tract carcinoma (BTC) that

FDA Approval of Ryoncil (Remestemcel-L): A New Frontier in Regenerative Medicine

Mesoblast Limited’s mesenchymal stem cell therapy, Ryoncil (Remestemcel-L), was recently approved by the U.S. Food and Drug Administration (FDA). This novel therapy is a major breakthrough in regenerative medicine and

An Update on mRNA Cancer Vaccines: A New Frontier in Oncology

With promising results from early-phase clinical trials and ongoing developments, mRNA cancer vaccines are poised to redefine cancer treatment strategies. Recent advancements in mRNA technology have brought about a paradigm

Enhancing Cancer Testing in India: Core Diagnostic is being acquired by Metropolis Healthcare

One of the top diagnostic chains in India, Metropolis Healthcare, has announced plans to buy Core Diagnostics, a specialized diagnostic company that specializes in advanced testing in precision medicine, genomics,

Breaking Barriers in Lung Cancer Treatment: The Impact of Lorlatinib

Lung cancer is one of the most prevalent and deadly forms of cancer worldwide. Despite advances in detection and treatment, it continues to pose significant challenges for patients and healthcare

A New Development in Immunotherapy for the Treatment of Nasopharyngeal Carcinoma: FDA Approves LOQTORZI

The U.S. Food and Drug Administration (FDA) has approved LOQTORZI (generic name: Lacnozalimab), a ground-breaking medication intended to boost the body’s immune response against a nasopharyngeal carcinoma (NPC), marking a

Breaking Barriers in Breast Cancer: Enhertu Shows Promise for HER2-Low Patients

For patients with HER2-low breast cancer, the medication Enhertu (fam-trastuzumab deruxtecan-nxki) has shown remarkable efficacy in lowering the risk of cancer metastasis, marking a revolutionary breakthrough in the treatment of

BrECADD: A Modern Approach to Advanced-Stage Classical Hodgkin Lymphoma Treatment

Classically, Hodgkin lymphoma (cHL) is highly treatable, yet its treatment for advanced stages is invariably hard to optimize. Long considered one of the cornerstones in the management of advanced-stage Hodgkin

Merus’s Bizengri: A Breakthrough finding in metastatic or advanced non-small cell lung cancer (NSCLC) and advanced unresectable or metastatic pancreatic adenocarcinoma

Bizengri, created by Merus N.V., is a potential development in the fast developing field of cancer therapies. Bizengri, which has recently drawn interest from the biotechnology and pharmaceutical industries, has